A double-blind confirmatory study comparing rapid acting intramuscular olanzapine and intramuscular placebo in agitated patients with schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2009
At a glance
- Drugs Olanzapine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 28 Aug 2009 Actual patient number changed from 33 to 34 as reported by ClinicalTrials.gov.
- 17 Aug 2008 Actual patient number added (33) as reported by ClinicalTrials.gov.
- 17 Aug 2008 Actual end date added (July 2008) as reported by ClinicalTrials.gov.